Can a targeted pill tame severe COVID-19?
NCT ID NCT05713279
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This trial is testing whether adding flunotinib, an experimental drug that targets inflammation, to standard antiviral treatment can help people hospitalized with severe COVID-19. The study includes adults with confirmed COVID-19 who are getting worse despite standard care. The main goal is to see if the combination reduces the need for breathing support or death within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- flunotinib maleate tablets combined with standard antiviral therapy
- What this could lead to
- If effective, this combination could offer a new way to reduce severe COVID-19 complications, such as the need for breathing support or death.
- What could go wrong
- This is a very small early trial with only 13 participants, so results may not apply broadly. The drug may not improve outcomes and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chengdu Zenitar Biomedical Technology Co., Ltd
Chengdu, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?
- Can a quick online game train people to spot COVID-19 lies?